STING1 and familial pancreatic carcinoma: This innovative Exo‐based delivery platform offers a promising strategy for achieving stable STING pathway activation and precise immune modulation within the TME using a single integrated system, ultimately improving the efficacy and safety of pancreatic cancer immunotherapy.